Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 1:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3025–3048 of 3,928 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Congenital Heart Disease, Pulmonary Hypertension
Interventions: Magnetic Resonance Imaging; Other
Lead sponsor: Stanford University; Other
Eligibility: Not listed
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2029
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Uncontrolled Hypertension, Chronic Kidney Diseases
Interventions: CIN-107, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 71
States / cities: Birmingham, Alabama • Huntsville, Alabama • Beverly Hills, California + 65 more

Conditions: Pre-Eclampsia
Interventions: Not listed
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hypertension, Perioperative Hypertension
Interventions: Anesthesiologist phone call; Other
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Tadalafil, placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 40 Years to 85 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 5
States / cities: West Los Angeles, California • Denver, Colorado • Decatur, Georgia + 2 more

Conditions: Blood Pressure, Hypertension
Interventions: Dextrose 20 % in 500 ML Injection, Intralipid, Saline, Ascorbic acid; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years to 79 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Cardiovascular Diseases, Hypertension, Postmenopausal, Overweight or Obese
Interventions: Exercise; Behavioral
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 45 Years to 75 Years · Female only
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Hypertension
Interventions: Valsartan, Enalapril; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Hypertension
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypertension
Interventions: Nebivolol, Metoprolol succinate; Drug
Lead sponsor: Emory University; Other
Eligibility: 21 Years to 80 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Glaucoma, Quality of Life
Interventions: Clinical evaluation, Performance based measures, Subjective measures of vision-related quality of life; Other
Lead sponsor: Wills Eye; Other
Eligibility: 18 Years to 80 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Desaturation, Bradycardia, Tachycardia, Hypertension, Hypotension
Interventions: Rapid Response Team (NTX wireless monitoring system); Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1,303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Open-Angle Glaucoma
Interventions: XEN45 (Glaucoma Gel Stent); Device
Lead sponsor: AbbVie; Industry
Eligibility: 45 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 23
States / cities: Fayetteville, Arkansas • Pasadena, California • Ventura, California + 19 more

Conditions: Hypertension, Adolescent Behavior, Health Knowledge, Attitudes, Practice
Interventions: Youth-Led Hypertension Education Digital Intervention; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 14 Years and older
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Depression, Hypertension
Interventions: Mindfulness-Based Stress Reduction (MBSR; CALM-Chicago Study); Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Preeclampsia
Interventions: Not listed
Lead sponsor: Catalin S Buhimschi, MD; Other
Eligibility: 18 Years to 48 Years · Female only
Enrollment: 346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Diabetes Mellitus, Hypertension, Hyperlipidemia
Interventions: Pre-filled trays; Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypertension
Interventions: acupuncture, sham needle treatment; Device
Lead sponsor: Logan College of Chiropractic; Other
Eligibility: 20 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 1
States / cities: Chesterfield, Missouri

Conditions: Obesity, Hyperlipidemia, Insulin Resistance, Hypertension
Interventions: Glutathione, N-Acetylcysteine, Placebo; Dietary Supplement · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Stanford, California

Conditions: Hypertension
Interventions: Clevidipine; Drug
Lead sponsor: Mario Ammirati; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Pediatric Hypertension
Interventions: NICHE method, Usual care, Amlodipine, Lisinopril, Hydrochlorothiazide, Losartan; Other · Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 10 Years to 22 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: High Dose Device, Low Dose Device, Placebo Device; Drug · Device
Lead sponsor: Vistakon Pharmaceuticals; Industry
Eligibility: 21 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 4
States / cities: Artesia, California • Louisville, Kentucky • Baltimore, Maryland + 1 more

Conditions: Mild Cognitive Impairment
Interventions: Placebo, Candesartan; Drug
Lead sponsor: Emory University; Other
Eligibility: 50 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: AR-12286 0.5% Ophthalmic Solution; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: San Diego, California

Search by objective public record fields.

MRI and Computational Simulation Cardiology Study

A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease

Placental Volume, Flow, and Vascularity Study

The Effectiveness of a Preoperative Blood Pressure Screening Program to Identify Undiagnosed Hypertension in Ambulatory Surgery Patients

Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease

Reversing Glucose and Lipid-mediated Vascular Dysfunction

Dose-Response to Exercise in Women Aged 45-75 Years (DREW)

Effect of Valsartan Compared to Enalapril on Sitting Systolic Blood Pressure in Children With High Blood Pressure

Patient-Provider Communication and Medication Adherence

Effect of Nebivolol on Oxidative Stress and Endothelial Progenitor Cells

How Has Glaucoma Affected Your Quality of Life?

Validation of the NTX Wireless Patient Monitoring System

Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma

Youth-Led Intervention to Improve Blood Pressure

Community-based Approach to Lowering Stress Through Mindfulness

The Clinical Utility of the Congo-Red Dot Test for Diagnosis and Early Prediction of Preeclampsia During Pregnancy

Effects of Use of a Connected Pillbox On Medication Adherence

The Effect of Acupuncture on Blood Pressure and Heart Rate Variability (HRV)

Effects of Glutathione (an Antioxidant) and N-Acetylcysteine on Inflammation

The Evaluation of Clevidipine in Patients Requiring ICP Monitoring and IV Antihypertensive Therapy

N-of-1 Trials In Children With Hypertension

Safety and Efficacy of a Glaucoma Drug Delivery System

Candesartan's Effects on Alzheimer's Disease And Related Biomarkers

24-hour Efficacy of AR-12286